J Cancer 2021; 12(10):2975-2981. doi:10.7150/jca.56207 This issue Cite

Research Paper

Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study

Li Ye1,2, Chen Mei1,2, Yanling Ren1,2, Xinping Zhou1,2, Liya Ma1,2, Weilai Xu1,2, Juying Wei1,2, Huifang Jiang3, Liming Zhang4, Hui Zeng5, Hongyan Tong1,2✉

1. MDS Center, Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
2. Key Laboratory of Hematologic Malignancies of Zhejiang Province, Hangzhou 310009, Zhejiang Province, China.
3. Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang Province, China.
4. Department of Hematology, Zhuji People's Hospital of Zhejiang Province, Zhuji 311800, Zhejiang Province, China.
5. Institute of Hematology, the First Hospital of Jiaxing City in Zhejiang Province, Jiaxing 314001, Zhejiang Province, China.

Citation:
Ye L, Mei C, Ren Y, Zhou X, Ma L, Xu W, Wei J, Jiang H, Zhang L, Zeng H, Tong H. Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study. J Cancer 2021; 12(10):2975-2981. doi:10.7150/jca.56207. https://www.jcancer.org/v12p2975.htm
Other styles

File import instruction

Abstract

Graphic abstract

Purpose: To explore the efficacy and safety of lower-dose decitabine in patients with lower-risk MDS, a prospective multicenter phase II study was conducted to compare decitabine with the best supportive care (BSC).

Methods: Patients diagnosed with lower-risk MDS from September 2013 to August 2018 were assigned to the decitabine group or the BSC group. Decitabine (12 mg/m2/day) was administered over 1 hour/day for 5 consecutive days in a 4-week cycle. BSC, including growth factors, transfusion, thalidomide, lenalidomide, and immunosuppressive agents were given consecutively. The endpoints included the proportion of patients who achieved overall response (OR) in the first 2 or 3 courses, event-free survival (EFS), and overall survival (OS).

Results: A total of recruited 82 patients were analyzed. In the decitabine group, 65.9% (27/41) achieved OR after 2 or 3 cycles of treatment, compared with 22.0% (9/41) in the BSC group (p <0.01). Besides, 44.0% (11/25) in the decitabine group became independent of RBC/Platelets transfusion, compared with 27.8% (5/18) in the BSC group. Patients with gene mutation and treated with decitabine achieved a higher OR rate, compared with those without gene mutation [72.0% (18/25) vs 11.5% (3/26), p <0.01]. There was no significant difference in the median EFS between the decitabine and BSC groups (20.6 vs 14.3 months respectively, p = 0.665). In the decitabine group, the most significant adverse events were infections of any grades or neutropenic fever (46.3%, 19/41) and one patient (4.2%) died of acute cerebral infarction within 6 weeks of treatment.

Conclusion: Lower-dose decitabine demonstrated promising clinical response with acceptable toxicity profiles in patients with low- and intermediate 1-risk MDS. A higher response rate to decitabine was observed in patients with mutated genes. Therefore, lower-dose decitabine can be advocated for patients with low-risk MDS and mutated genes.

Keywords: myelodysplastic syndromes, lower risk, hypomethylating


Citation styles

APA
Ye, L., Mei, C., Ren, Y., Zhou, X., Ma, L., Xu, W., Wei, J., Jiang, H., Zhang, L., Zeng, H., Tong, H. (2021). Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study. Journal of Cancer, 12(10), 2975-2981. https://doi.org/10.7150/jca.56207.

ACS
Ye, L.; Mei, C.; Ren, Y.; Zhou, X.; Ma, L.; Xu, W.; Wei, J.; Jiang, H.; Zhang, L.; Zeng, H.; Tong, H. Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study. J. Cancer 2021, 12 (10), 2975-2981. DOI: 10.7150/jca.56207.

NLM
Ye L, Mei C, Ren Y, Zhou X, Ma L, Xu W, Wei J, Jiang H, Zhang L, Zeng H, Tong H. Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study. J Cancer 2021; 12(10):2975-2981. doi:10.7150/jca.56207. https://www.jcancer.org/v12p2975.htm

CSE
Ye L, Mei C, Ren Y, Zhou X, Ma L, Xu W, Wei J, Jiang H, Zhang L, Zeng H, Tong H. 2021. Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study. J Cancer. 12(10):2975-2981.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image